NCT01595841View on ClinicalTrials.gov

Sirolimus Use in Angioplasty for Vascular Access Extension

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions
End Stage Renal DiseaseVenous Stenosis
Interventions
DRUG

Sirolimus

3 mg po od loading dose for two days, then 2 mg po od for thirty days

Trial Locations (1)

N6A 5A5

London Health Sciences Centre, London

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER